AbbVie expects these two drugs to generate more than $31 billion in sales in 2026 — about $0.5 billion above its long-term ...

We are thrilled to welcome Elaine to Artiva’s board at such an important time for the company,” said Fred Aslan, M.D., president and chief executive officer of Artiva Biotherapeutics. “Elaine brings ...

AbbVie recently reported record 2025 results and outlined a stronger 2026 outlook, while advancing key immunology assets and ...

Vicks took the top spot ahead of Rinvoq, Skyrizi and Tremfya, which continue to be the top spenders on national TV pharma ads.

The global pharmaceutical market, now valued at roughly $1.7 trillion, continues to expand. With nearly $4.9 trillion spent annually on healthcare in the U.S. alone—half of the worldwide ...

AbbVie’s fourth quarter results came in above Wall Street’s revenue and profit expectations, but the market responded ...

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

AbbVie Inc. (NYSE:ABBV) Q4 2025 Earnings Call Transcript February 4, 2026 AbbVie Inc. beats earnings expectations. Reported EPS is $2.71, expectations were $2.65. Operator: Good morning, and thank you ...

Pharmaceutical company AbbVie (NYSE:ABBV) in Q4 CY2025, but sales rose 6% year on year to $16 billion. Its non-GAAP profit of $2.71 per share was 2.2% above analysts’ consensus estimates. Is now the ...

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. AbbVie has submitted regulatory applications in the US and Europe for Rinvoq as a ...

AbbVie's settlement extends Rinvoq's patent protection by 12 years, enhancing market exclusivity and sales projections. Rinvoq's sales have reached $6 billion, with expectations to surpass $12 billion ...